- 1.
Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation. Eur Heart J 2010; 31: 2369 – 429.
- 2.
Baxter K. (red.) Stockley’s drug interactions. 8. utg. London: The Pharmaceutical Press, 2008: 916 – 7.
- 3.
Berg JP, Hanssen KF, Bjerve KS et al. Standardisert hemoglobin A1c til diagnostisk bruk. Tidsskr Nor Legeforen 2011; 131: 565-6.
- 4.
Amato L, Paolisso G, Cacciatore F et al. Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. Diabetes Metab 1997; 23: 213 – 8.
- 5.
Tenenbaum A, Motro M, Fisman EZ et al. Functional class in patients with heart failure is associated with the development of diabetes. Am J Med 2003; 114: 271 – 5.
- 6.
Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239 – 45.
- 7.
Statens legemiddelverk. Preparatomtale (SPC) Digitoxin. www.legemiddelverket.no/preparatomtaler (25.8.2011).
- 8.
Spigset O, Mjörndal T. Increased glucose intolerance related to digoxin treatment in patients with type 2 diabetes mellitus. J Intern Med 1999; 246: 419 – 22.
- 9.
Krusteva E. Effect of digoxin on experimental adrenaline-induced hyperglycemia and insulin-induced hypoglycemia. Folia Med (Plovdiv) 1992; 34: 14 – 6.
- 10.
Bagrov YY, Manusova NB, Egorova IA et al. Marinobufagenin, an endogenous inhibitor of alpha-1 Na/K-ATPase, is a novel factor in pathogenesis of diabetes mellitus. Dokl Biol Sci 2005; 404: 333 – 7.
- 11.
Riganti C, Campia I, Kopecka J et al. Pleiotropic effects of cardioactive glycosides. Curr Med Chem 2011; 18: 872 – 85.
- 12.
The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525 – 33.
- 13.
Ahmed A, Aban IB, Vaccarino V et al. A propensity-matched study of the effect of diabetes on the natural history of heart failure: variations by sex and age. Heart 2007; 93: 1584 – 90.
- 14.
MacDonald MR, Petrie MC, Hawkins NM et al. Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J 2008; 29: 1224 – 40.
- 15.
Preiss D, Zetterstrand S, McMurray JJV et al. Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. Diabetes Care 2009; 32: 915 – 20.
()
Denne artikkelen ble publisert for mer enn 12 måneder siden, og vi har derfor stengt for nye kommentarer.